Insights
Search Results
Alerts
8.18.26
CMS Proposes Changes to Incentivize FHIR-enabled Electronic Prior Authorization Use
On July 14, 2026, the Centers for Medicare & Medicaid Services (CMS) announced the CY 2027 Physician Fee Schedule (PFS) proposed rule. The proposed rule includes modifications to further incentivize the use of electronic prior authorization in Medicare Ambulatory Specialty Models (ASMs) and the Merit-based Incentive Payment System (MIPS) by health care providers. This builds on prior CMS regulations related to prior authorization which imposed requirements on certain health plans, but not on health care providers (see 2024 CMS Interoperability and Prior Authorization final rule). These changes are not “PFS” in the technical sense of altering relative value unit (RVU) or conversion-factor payment calculations, but rather are Quality Payment Program (QPP) and Center for Medicare and Medicaid Innovation (CMMI) policy changes that are included in the same omnibus annual rulemaking package. For CMS’s proposed PFS and Hospital Outpatient Prospective Payment System (OPPS) payment changes, see our previous client alert, “Health Reimbursement Signals: CMS Proposes Payment Frameworks for ‘Software as a Medical Service.’”1
Client Highlights
8.06.26
Wilson Sonsini Advises Cylinder Health on $105 Million Acquisition by Hinge Health
On August 4, 2026, Hinge Health, a digital healthcare company, announced that it has signed a definitive agreement to acquire Cylinder Health, a leader in virtual-first digestive healthcare, for $105 million in cash consideration. Wilson Sonsini Goodrich & Rosati advised Cylinder Health on the transaction.
Alerts
7.23.26
Health Reimbursement Signals: CMS Proposes Payment Frameworks for “Software as a Medical Service”
On July 2, 2026, the Centers for Medicare and Medicaid Services (CMS) released the calendar year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule and on July 14, 2026, subsequently released the CY 2027 Physician Fee Schedule (PFS) proposed rule.1 These proposed rules establish a newly named Medicare payment category, Software as a Medical Service (SaMS), for software that supports clinical decision-making through algorithmic analysis.2 This is CMS’ first effort to pay for software-based clinical services in a structural way as their own category rather than as a cost buried inside reimbursement for another procedure. The consequential impact is that CMS would create a new reimbursement vehicle for software and AI-enabled products to be reimbursed as standalone services in the future. The proposal is worth close attention from stakeholders because Medicare reimbursement often determines the success of software or AI products intended for clinical purposes. Comments are due August 31, 2026, on the OPPS rule and September 14, 2026, on the PFS rule.
Client Highlights
6.24.26
Wilson Sonsini Advises Assort Health on $120 Million Series C
On June 24, 2026, Assort Health, the most widely used AI agents platform for the patient journey, announced a $120 million Series C led by Menlo Ventures at a valuation of $1.2 billion. Assort has now raised more than $222 million to become the standard for healthcare organizations wanting to transform the patient journey with AI. Wilson Sonsini Goodrich & Rosati advised Assort on the transaction.
In addition to Menlo Ventures, investors participating in the Series C financing include Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Joe Montana, Tau Ventures, and Quiet Capital.
What began as the first voice AI agent to schedule a specialty appointment is now a platform spanning scheduling, intake forms, referrals, document processing, medication refills, real time eligibility, lab requests, and payments. That expansion has been powered by more than 190 million patient interactions, 62,000 care protocols, and 1.6 million decision pathways, creating the largest proprietary specialty dataset in healthcare.
The Wilson Sonsini team that advised Assort on the financing included Lang Liu, Alex Youssef, Madisyn Klein, and Nara Jo.
For more information, please see Assort’s blog post.
In addition to Menlo Ventures, investors participating in the Series C financing include Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Joe Montana, Tau Ventures, and Quiet Capital.
What began as the first voice AI agent to schedule a specialty appointment is now a platform spanning scheduling, intake forms, referrals, document processing, medication refills, real time eligibility, lab requests, and payments. That expansion has been powered by more than 190 million patient interactions, 62,000 care protocols, and 1.6 million decision pathways, creating the largest proprietary specialty dataset in healthcare.
The Wilson Sonsini team that advised Assort on the financing included Lang Liu, Alex Youssef, Madisyn Klein, and Nara Jo.
For more information, please see Assort’s blog post.
Newsletters
6.23.26
All Eyes on AI: Regulatory, Litigation, and Transactional Developments – Q1 2026
Wilson Sonsini is pleased to present the next edition of All Eyes on AI: Regulatory, Litigation, and Transactional Developments, which closely follows the evolving regulatory landscape for artificial intelligence (AI) in the U.S., new EU regulations for AI, international developments, litigation, recent deal highlights, firm publications, and other AI and machine learning highlights.
Newsletters
6.03.26
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.
Alerts
5.19.26
Colorado Legislature Repeals and Replaces Colorado AI Act: What SB 189 Means for Your Business
On May 14, 2026, Colorado Governor Jared Polis signed SB 189 into law, which repeals and replaces the Colorado Artificial Intelligence Act (CAIA). SB 189 goes into effect on January 1, 2027.
Client Highlights
4.13.26
Wilson Sonsini Advises Ultralight on $9.3 Million Seed Funding
On April 13, 2026, Ultralight, the AI-native operating system for modern medicine, announced that it has raised $9.3 million in seed funding. The round was led by The General Partnership, with participation from Wisdom Ventures, Anthemis Group, Emerson Collective, GSBackers, and various angel investors. Wilson Sonsini Goodrich & Rosati advised Ultralight on the transaction.
Ultralight’s platform automates busywork, surfaces deep clinical insights, and frees clinicians to practice high-touch medicine. Designed for clinicians who lead functional, integrative, or longevity practices, Ultralight unifies electronic health records, practice management, and patient engagement in one vertical SaaS stack, with powerful AI natively built in.
The Wilson Sonsini team that advised Ultralight on the financing includes Lang Liu and Oliver Zhou.
For more information, please see Ultralight CEO Sunita Mohanty’s LinkedIn post and this Axios article.
Ultralight’s platform automates busywork, surfaces deep clinical insights, and frees clinicians to practice high-touch medicine. Designed for clinicians who lead functional, integrative, or longevity practices, Ultralight unifies electronic health records, practice management, and patient engagement in one vertical SaaS stack, with powerful AI natively built in.
The Wilson Sonsini team that advised Ultralight on the financing includes Lang Liu and Oliver Zhou.
For more information, please see Ultralight CEO Sunita Mohanty’s LinkedIn post and this Axios article.
Alerts
4.06.26
FTC Announcement of Healthcare Task Force Coincides with Joint DOJ/FTC Appearance at ONC Annual Meeting
Two recent developments suggest that enforcers are poised to grapple with antitrust concerns in health tech, signaling an escalation of scrutiny into Information Blocking1 tactics that have persisted despite U.S. Department of Health and Human Services (HHS) rules and regulations designed to curtail such practices. Stakeholders and industry participants should be prepared for potential outreach.
Client Highlights
3.24.26
Firm Advises Dimer Health on $13.5 Million Series A Financing
On March 23, 2026, Dimer Health, a clinician-led, AI-native transitional care medicine company, announced $13.5 million in Series A financing led by Team8 and Bill Ackman's Table Management, with participation from existing investors Silver Circle and TechAviv. The round brings the company's total funding to $20 million and will support national expansion of Dimer's dedicated post-discharge clinical service line, now operating across eight states. Wilson Sonsini Goodrich & Rosati advised Dimer on the transaction.
Newsletters
1.29.26
All Eyes on AI: Regulatory, Litigation, and Transactional Developments - Q3/Q4 2025
Wilson Sonsini’s All Eyes on AI: Regulatory, Litigation, and Transactional Developments closely follows the evolving regulatory landscape for artificial intelligence (AI) in the U.S., new EU regulations for AI, international developments, litigation, recent deals highlights, firm publications, and other AI and machine learning highlights. This latest Q3/Q4 2025 edition features: